Viking Therapeutics, Inc. (VKTX) Balance Sheet
As of 2026-06-30 (10-Q), Viking Therapeutics, Inc. (VKTX) reported total assets of $521.9M, total liabilities of $113.6M and shareholders' equity of $408.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $125.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VKTXViking Therapeutics, Inc.Follow VKTX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.8 | 3.1 | 9.0 | 24.8 | 8.4 | 29.1 | 26.4 | 36.6 | 55.5 | 26.7 | 165.8 | 125.8 | |
| Short-term investments | 13.3 | 10.1 | 11.6 | 276.7 | 267.3 | 219.3 | 175.7 | 118.9 | 306.6 | 875.9 | 539.9 | 375.9 | |
| Current assets | 15.2 | 14.0 | 21.9 | 302.1 | 283.5 | 256.1 | 210.5 | 167.0 | 367.2 | 907.2 | 715.6 | 517.6 | |
| Total assets | 15.4 | 14.5 | 22.1 | 302.3 | 284.3 | 256.5 | 210.7 | 168.5 | 368.5 | 908.3 | 715.7 | 521.9 | |
| Current liabilities | 2.0 | 6.5 | 8.7 | 4.6 | 6.8 | 12.1 | 8.8 | 21.9 | 19.1 | 27.4 | 76.7 | 109.7 | |
| Short-term debt | — | 3.3 | 3.5 | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 6.7 | 6.5 | 8.7 | 4.6 | 7.1 | 12.2 | 8.8 | 23.2 | 20.1 | 28.0 | 76.7 | 113.6 | |
| Shareholders' equity | 8.7 | 8.0 | 13.5 | 297.8 | 277.1 | 244.3 | 201.9 | 145.3 | 348.4 | 880.3 | 639.1 | 408.3 |
USD millions · SEC XBRL
Viking Therapeutics, Inc. — questions
- How much cash does Viking Therapeutics, Inc. have?
- $125.8M in cash and cash equivalents as of 2026-06-30.
- What are Viking Therapeutics, Inc.'s total assets?
- $521.9M as of 2026-06-30.
- What is Viking Therapeutics, Inc.'s shareholders' equity?
- $408.3M as of 2026-06-30.
Every figure on this page comes from Viking Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.